Tom De Potter1, Hugo Van Herendael2, Richard Balasubramaniam3, Matthew Wright4, Decebal-Gabriel Laţcu5, Sharad C Agarwal6, Baohui Zhang7, Lee Ming Boo7, Antonio Pani8. 1. OLV Hospital, Aalst, Belgium. 2. Ziekenhuis Oost-Limburg, Genk, Belgium. 3. Royal Bournemouth Hospital, Bournemouth, UK. 4. Division of Imaging Sciences and Biomedical Engineering, King's College London and Department of Cardiology, St. Thomas' Hospital, London, UK. 5. CH Princesse Grace, Monaco, Monaco. 6. Papworth Hospital NHS Foundation Trust, Cambridge, UK. 7. Biosense Webster, Inc., California, USA. 8. Struttura di Cardiologia, Lecco, Italy.
Abstract
BACKGROUND: To investigate the real-world clinical experience of persistent atrial fibrillation (persAF) ablation using the THERMOCOOL SMARTTOUCH® catheter with contact force (CF)-sensing ability in a prospective, multicenter registry. METHODS: Patients with persAF (excluding long-standing persAF) undergoing ablation were enrolled. Primary adverse events (AEs), 12-month success, quality of life (QoL), and correlation of success with CF were assessed. RESULTS: Overall, 150 patients with persAF (age 61.6 ± 9.4 years; 76.0% male; 90.7% Caucasian; left ventricular ejection fraction 56.9% ± 10.3%; left atrial diameter 41.5 ± 7.9 mm) underwent catheter insertion (safety cohort); 142 met eligibility criteria and were ablated (evaluable cohort). Confirmation of entrance block for all targeted pulmonary veins was achieved in 99.3% of patients. The primary AE rate was 4.0% (6/150), and 12-month success was 63.1% (95% confidence interval: 54.2%-71.4%). A non-significant trend towards higher success was observed in patients with isoproterenol/adenosine challenge vs. those without (73.1% vs. 60.2%, respectively; P=0.065). Investigators stayed within their pre-selected CF working range (catheter-tissue contact stability) 79.7% ± 12.7% of the time. When investigators stayed within the CF range ≥80% vs. <80% of the time, ablation success was 69.2% vs. 58.5%, respectively (P=0.285). QoL improved significantly at 6 months and was sustained through the 12-month follow-up (P<0.0001). CONCLUSIONS: Symptom control in a real-world setting of persAF ablation using the THERMOCOOL SMARTTOUCH® catheter was 63.1%, with significant improvements in QoL, and trended non-significantly towards increased success in patients receiving isoproterenol/adenosine challenge and when investigators stayed within their pre-selected CF range ≥80% of the time.
BACKGROUND: To investigate the real-world clinical experience of persistent atrial fibrillation (persAF) ablation using the THERMOCOOL SMARTTOUCH® catheter with contact force (CF)-sensing ability in a prospective, multicenter registry. METHODS: Patients with persAF (excluding long-standing persAF) undergoing ablation were enrolled. Primary adverse events (AEs), 12-month success, quality of life (QoL), and correlation of success with CF were assessed. RESULTS: Overall, 150 patients with persAF (age 61.6 ± 9.4 years; 76.0% male; 90.7% Caucasian; left ventricular ejection fraction 56.9% ± 10.3%; left atrial diameter 41.5 ± 7.9 mm) underwent catheter insertion (safety cohort); 142 met eligibility criteria and were ablated (evaluable cohort). Confirmation of entrance block for all targeted pulmonary veins was achieved in 99.3% of patients. The primary AE rate was 4.0% (6/150), and 12-month success was 63.1% (95% confidence interval: 54.2%-71.4%). A non-significant trend towards higher success was observed in patients with isoproterenol/adenosine challenge vs. those without (73.1% vs. 60.2%, respectively; P=0.065). Investigators stayed within their pre-selected CF working range (catheter-tissue contact stability) 79.7% ± 12.7% of the time. When investigators stayed within the CF range ≥80% vs. <80% of the time, ablation success was 69.2% vs. 58.5%, respectively (P=0.285). QoL improved significantly at 6 months and was sustained through the 12-month follow-up (P<0.0001). CONCLUSIONS: Symptom control in a real-world setting of persAF ablation using the THERMOCOOL SMARTTOUCH® catheter was 63.1%, with significant improvements in QoL, and trended non-significantly towards increased success in patients receiving isoproterenol/adenosine challenge and when investigators stayed within their pre-selected CF range ≥80% of the time.
Authors: Valentin Fuster; Lars E Rydén; Davis S Cannom; Harry J Crijns; Anne B Curtis; Kenneth A Ellenbogen; Jonathan L Halperin; G Neal Kay; Jean-Yves Le Huezey; James E Lowe; S Bertil Olsson; Eric N Prystowsky; Juan Luis Tamargo; L Samuel Wann Journal: J Am Coll Cardiol Date: 2011-03-15 Impact factor: 24.094
Authors: Matthew C Henn; Timothy S Lancaster; Jacob R Miller; Laurie A Sinn; Richard B Schuessler; Marc R Moon; Spencer J Melby; Hersh S Maniar; Ralph J Damiano Journal: J Thorac Cardiovasc Surg Date: 2015-08-08 Impact factor: 5.209
Authors: Vivek Y Reddy; Scott Pollak; Bruce D Lindsay; H Thomas McElderry; Andrea Natale; Charan Kantipudi; Moussa Mansour; Daniel P Melby; Dhanunjaya Lakkireddy; Tzachi Levy; David Izraeli; Chithra Sangli; David Wilber Journal: JACC Clin Electrophysiol Date: 2016-11-21
Authors: Nassir F Marrouche; David Wilber; Gerhard Hindricks; Pierre Jais; Nazem Akoum; Francis Marchlinski; Eugene Kholmovski; Nathan Burgon; Nan Hu; Lluis Mont; Thomas Deneke; Mattias Duytschaever; Thomas Neumann; Moussa Mansour; Christian Mahnkopf; Bengt Herweg; Emile Daoud; Erik Wissner; Paul Bansmann; Johannes Brachmann Journal: JAMA Date: 2014-02-05 Impact factor: 56.272
Authors: David J Wilber; Carlo Pappone; Petr Neuzil; Angelo De Paola; Frank Marchlinski; Andrea Natale; Laurent Macle; Emile G Daoud; Hugh Calkins; Burr Hall; Vivek Reddy; Giuseppe Augello; Matthew R Reynolds; Chandan Vinekar; Christine Y Liu; Scott M Berry; Donald A Berry Journal: JAMA Date: 2010-01-27 Impact factor: 56.272